Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Prostate Cancer

  Free Subscription


15.04.2024

1 BJU Int
2 BMC Cancer
1 BMC Urol
1 Cancer Res
2 Clin Cancer Res
1 Discov Oncol
1 Eur Urol
1 Int J Cancer
2 J Magn Reson Imaging
2 J Nucl Med
5 J Urol
3 JAMA
1 Mod Pathol
1 Mol Ther Oncol
1 Oncogene
1 PLoS Comput Biol
1 PLoS One
2 Prostate


   Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    BJU Int

  1. BERRIDGE C, Omer A, Lopez F, Bryant RJ, et al
    Perspectives on technology - prostate cancer: is local anaesthetic transperineal prostate biopsy really better than transrectal biopsy?
    BJU Int. 2024 Apr 8. doi: 10.1111/bju.16349.
    PubMed         Abstract available


    BMC Cancer

  2. FREDMAN E, Icht O, Moore A, Bragilovski D, et al
    SABR-Dual: a phase II/III trial of two-fraction versus five-fraction stereotactic radiotherapy for localized low- and favorable intermediate-risk prostate cancer.
    BMC Cancer. 2024;24:431.
    PubMed         Abstract available

  3. DUAN L, Liu Z, Wan F, Dai B, et al
    Advantage of whole-mount histopathology in prostate cancer: current applications and future prospects.
    BMC Cancer. 2024;24:448.
    PubMed         Abstract available


    BMC Urol

  4. SHIMIZU R, Morizane S, Yamamoto A, Yamane H, et al
    Assessment of the accuracy of biparametric MRI/TRUS fusion-guided biopsy for index tumor evaluation using postoperative pathology specimens.
    BMC Urol. 2024;24:79.
    PubMed         Abstract available


    Cancer Res

  5. MURPHY S, Rahmy S, Gan D, Liu G, et al
    Ketogenic diet alters the epigenetic and immune landscape of prostate cancer to overcome resistance to immune checkpoint blockade therapy.
    Cancer Res. 2024 Apr 8. doi: 10.1158/0008-5472.CAN-23-2742.
    PubMed         Abstract available


    Clin Cancer Res

  6. SCHATZ CA, Zitzmann-Kolbe S, Moen I, Klotz M, et al
    Preclinical efficacy of a PSMA-targeted actinium-225 conjugate (225Ac-macropa-pelgifatamab) - a targeted alpha therapy for prostate cancer.
    Clin Cancer Res. 2024 Apr 9. doi: 10.1158/1078-0432.CCR-23-3746.
    PubMed         Abstract available

  7. CHO H, Byun SS, Son NH, Chung JI, et al
    Impact of Circulating Tumor Cell-Expressed Prostate-Specific Membrane Antigen and Prostate-Specific Antigen Transcripts in Different Stages of Prostate Cancer.
    Clin Cancer Res. 2024 Apr 8:OF1-OF13. doi: 10.1158/1078-0432.CCR-23-3083.
    PubMed         Abstract available


    Discov Oncol

  8. CHENG L, Li S, Jiang D, Zhang J, et al
    DSCAM-AS1 promotes the development of prostate cancer.
    Discov Oncol. 2024;15:113.
    PubMed         Abstract available


    Eur Urol

  9. RUSH HL, Gilbert DC, Langley RE
    Re: Bertrand Tombal, Sean Collins, Alicia K. Morgans, et al. Impact of Relugolix Versus Leuprolide on the Quality of Life of Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study. Eur Urol 2023;84:579-87.
    Eur Urol. 2024 Apr 6:S0302-2838(24)02251-6. doi: 10.1016/j.eururo.2024.
    PubMed        


    Int J Cancer

  10. WEISS S, Lamy P, Rusan M, Norgaard M, et al
    Exploring the tumor genomic landscape of aggressive prostate cancer by whole-genome sequencing of tissue or liquid biopsies.
    Int J Cancer. 2024 Apr 11. doi: 10.1002/ijc.34949.
    PubMed         Abstract available


    J Magn Reson Imaging

  11. BLEKER J, Roest C, Yakar D, Huisman H, et al
    The Effect of Image Resampling on the Performance of Radiomics-Based Artificial Intelligence in Multicenter Prostate MRI.
    J Magn Reson Imaging. 2023 Aug 12. doi: 10.1002/jmri.28935.
    PubMed         Abstract available

  12. THIEL TA, Valentin B, Ullrich T, Boschheidgen M, et al
    Spectral Diffusion Analysis in Patients With High Risk for Prostate Cancer: A Feasibility Study.
    J Magn Reson Imaging. 2024 Apr 5. doi: 10.1002/jmri.29354.
    PubMed        


    J Nucl Med

  13. VISCUSE P, Devitt M, Dreicer R
    Clinical Management of Advanced Prostate Cancer: Where Does Radiopharmaceutical Therapy Fit in the Treatment Algorithm?
    J Nucl Med. 2024 Apr 11:jnumed.123.267006. doi: 10.2967/jnumed.123.267006.
    PubMed         Abstract available

  14. BAUCKNEHT M, Fornarini G, Di Raimondo T, Pardini M, et al
    Brain Metabolic Correlates of the Off-Target Effects of Enzalutamide on the Central Nervous System of Patients with Advanced Prostate Cancer.
    J Nucl Med. 2024 Apr 11:jnumed.124.267526. doi: 10.2967/jnumed.124.267526.
    PubMed        


    J Urol

  15. MIAN BM
    Reply: Complications Following Transrectal and Transperineal Prostate Biopsy: Results of the ProBE-PC Randomized Clinical Trial.
    J Urol. 2024;211:707-708.
    PubMed        

  16. MARIOTTI GC, Schmid BP, Gilberto GM, Garcia RG, et al
    Letter: Complications Following Transrectal and Transperineal Prostate Biopsy: Results of the ProBE-PC Randomized Clinical Trial.
    J Urol. 2024;211:707.
    PubMed        

  17. QIAN H, Chi C, Tricard T, Zhu Y, et al
    A Prospective Randomized Trial of Neoadjuvant Chemohormonal Therapy vs Hormonal Therapy in Locally Advanced Prostate Cancer Treated by Radical Prostatectomy.
    J Urol. 2024;211:648-655.
    PubMed         Abstract available

  18. RUMPF F, Plym A, Vaselkiv JB, Penney KL, et al
    Impact of Family History and Germline Genetic Risk Single Nucleotide Polymorphisms on Long-Term Outcomes of Favorable-Risk Prostate Cancer.
    J Urol. 2024 Apr 10:101097JU0000000000003927. doi: 10.1097/JU.0000000000003927.
    PubMed         Abstract available

  19. ST-LAURENT MP, Acland G, Hamilton SN, Hamm J, et al
    Long Term Second Malignancies in Prostate Cancer Patients Treated with Low-Dose-Rate Brachytherapy and Radical Prostatectomy.
    J Urol. 2024 Apr 11:101097JU0000000000003965. doi: 10.1097/JU.0000000000003965.
    PubMed         Abstract available


    JAMA

  20. AUVINEN A, Tammela TLJ, Mirtti T, Lilja H, et al
    Prostate Cancer Screening With PSA, Kallikrein Panel, and MRI: The ProScreen Randomized Trial.
    JAMA. 2024 Apr 6:e243841. doi: 10.1001/jama.2024.3841.
    PubMed         Abstract available

  21. TOSOIAN JJ, Penson DF, Chinnaiyan AM
    A Pragmatic Approach to Prostate Cancer Screening.
    JAMA. 2024 Apr 6. doi: 10.1001/jama.2024.4089.
    PubMed        

  22. MARTIN RM, Turner EL, Young GJ, Metcalfe C, et al
    Prostate-Specific Antigen Screening and 15-Year Prostate Cancer Mortality: A Secondary Analysis of the CAP Randomized Clinical Trial.
    JAMA. 2024 Apr 6:e244011. doi: 10.1001/jama.2024.4011.
    PubMed         Abstract available


    Mod Pathol

  23. PRENDEVILLE S, Kaur H, Ansari S, Alqaqa S, et al
    Somatic Tumor Testing in Prostate Cancer: Experience of a Tertiary-Care Center Including Pathologist-Driven Reflex Testing of Localized Tumors at Diagnosis.
    Mod Pathol. 2024 Apr 6:100489. doi: 10.1016/j.modpat.2024.100489.
    PubMed         Abstract available


    Mol Ther Oncol

  24. BOUTIN J, Genevois C, Couillaud F, Lamrissi-Garcia I, et al
    CRISPR editing to mimic porphyria combined with light: A new preclinical approach for prostate cancer.
    Mol Ther Oncol. 2024;32:200772.
    PubMed         Abstract available


    Oncogene

  25. LI Y, Lv L, Ye M, Xie N, et al
    PDIA2 has a dual function in promoting androgen deprivation therapy induced venous thrombosis events and castrate resistant prostate cancer progression.
    Oncogene. 2024 Apr 8. doi: 10.1038/s41388-024-03024.
    PubMed         Abstract available


    PLoS Comput Biol

  26. SHAH Y, Kulm S, Nauseef JT, Chen Z, et al
    Benchmarking multi-ancestry prostate cancer polygenic risk scores in a real-world cohort.
    PLoS Comput Biol. 2024;20:e1011990.
    PubMed         Abstract available


    PLoS One

  27. WU C, Zhu H, Zhang Y, Ding L, et al
    Interference with mitochondrial metabolism could serve as a potential therapeutic strategy for advanced prostate cancer.
    PLoS One. 2024;19:e0290753.
    PubMed         Abstract available


    Prostate

  28. CHAUDARY N, Wiljer E, Foltz W, Thapa P, et al
    An orthotopic prostate cancer model for new treatment development using syngeneic or patient-derived tumors.
    Prostate. 2024 Apr 12. doi: 10.1002/pros.24701.
    PubMed         Abstract available

  29. BROWN LK, Kanagasabai T, Li G, Celada SI, et al
    Co-targeting SKP2 and KDM5B inhibits prostate cancer progression by abrogating AKT signaling with induction of senescence and apoptosis.
    Prostate. 2024 Apr 11. doi: 10.1002/pros.24706.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.